SINTX Technologies, Inc. reported its financial results for the second quarter of 2026, revealing a total revenue of $452,000 for the three months ended June 30, 2026, a significant increase of 199% compared to $151,000 in the same period of 2025. For the first half of 2026, total revenue reached $832,000, up 60% from $520,000 in the prior year. The growth was primarily driven by a 347% increase in product revenue, which amounted to $447,000 in Q2 2026, compared to $100,000 in Q2 2025. The company attributed this increase to improved customer demand and the initial commercial sales of its SiNAPTIC Foot & Ankle Osteotomy Wedge System, which received FDA clearance in October 2025.
Despite the revenue growth, SINTX Technologies reported a net loss of $2.7 million for the second quarter of 2026, compared to a net loss of $2.3 million in the same quarter of 2025. For the six months ended June 30, 2026, the net loss was $5.5 million, an increase from $4.6 million in the prior year. The company’s operating expenses rose to $3.2 million in Q2 2026, up 16% from $2.7 million in Q2 2025, driven by higher general and administrative costs, which increased by 64% due to increased headcount and stock-based compensation.
Operationally, SINTX Technologies has made strategic moves to enhance its market position. The company has focused on its industrial business product line while also concentrating resources on high-growth areas within the healthcare sector. The company’s employee headcount has increased, reflecting its commitment to expanding its operational capabilities. As of June 30, 2026, SINTX had approximately 6.7 million shares of common stock outstanding, up from 4.0 million shares at the end of 2025, indicating a significant increase in equity financing activities.
The company continues to face challenges, including an accumulated deficit of $298 million as of June 30, 2026, and ongoing operating losses. SINTX Technologies has indicated that it is actively seeking additional funding through equity and debt financing to support its operations and growth initiatives. The management has expressed concerns about the company's ability to continue as a going concern for at least the next 12 months, contingent on its ability to increase sales and secure additional financing.
Looking ahead, SINTX Technologies aims to leverage its proprietary silicon nitride materials to expand its footprint in the medical device sector, particularly in orthopedic and spinal applications. The company is focused on commercializing its newly cleared medical technologies and advancing additional silicon nitride-based compositions. The management believes that the established industrial activities will provide a solid foundation for continued growth in the medical technology market, supporting long-term shareholder value creation.
About Sintx Technologies, Inc.
SINTX Technologies specializes in advanced ceramics, primarily silicon nitride, for biomedical and antipathogenic applications. Its core business includes manufacturing and developing implantable medical devices such as spinal fusion and joint replacement components, leveraging properties like biocompatibility, osteointegration, and antibacterial resistance. The company also explores antimicrobial surfaces and coatings, targeting healthcare markets worldwide with proprietary, FDA-registered manufacturing capabilities and a focus on innovation and regulatory compliance.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov